CIN-107 for Kidney Diseases

Phase-Based Progress Estimates
CinCor Site 42, Los Angeles, CA
Kidney Diseases+4 More
CIN-107 - Drug
All Sexes
What conditions do you have?

Study Summary

This study will evaluate the efficacy and safety of CIN-107 for the treatment of hypertension in patients with uncontrolled hypertension and Chronic Kidney Disease (CKD).

Eligible Conditions

  • Kidney Diseases
  • Hypertensive disease
  • Chronic Kidney Disease (CKD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Kidney Diseases

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: At Week 26

At Week 26
Change from baseline in SBP
Change from baseline in diastolic blood pressure (DBP)
Change from baseline in estimated glomerular filtration rate (eGFR)
Change from baseline in mean seated systolic blood pressure (SBP)
Change from baseline in urinary albumin-to-creatinine ratio (UACR)
Percentage of patients achieving SBP <130mmHg

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Kidney Diseases

Trial Design

3 Treatment Groups

Low dose CIN-107
1 of 3
High dose CIN-107
1 of 3
1 of 3
Experimental Treatment
Non-Treatment Group

300 Total Participants · 3 Treatment Groups

Primary Treatment: CIN-107 · Has Placebo Group · Phase 2

Low dose CIN-107
Experimental Group · 1 Intervention: CIN-107 · Intervention Types: Drug
High dose CIN-107
Experimental Group · 1 Intervention: CIN-107 · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 2

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: at week 26
Closest Location: CinCor Site 42 · Los Angeles, CA
Photo of Los Angeles 1Photo of Los Angeles 2Photo of Los Angeles 3
2022First Recorded Clinical Trial
1 TrialsResearching Kidney Diseases
2 CompletedClinical Trials

Who is running the clinical trial?

ParexelIndustry Sponsor
265 Previous Clinical Trials
94,654 Total Patients Enrolled
9 Trials studying Kidney Diseases
759 Patients Enrolled for Kidney Diseases
CinCor Pharma, Inc.Lead Sponsor
7 Previous Clinical Trials
894 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are taking an ACEi or ARB at the maximum tolerated daily dose.
You have a mean seated SBP of 140 mmHg or more.
You have a prior diagnosis of mild-to-severe chronic kidney disease.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.